Skip to main content
. 2020 Sep 10;11:2138. doi: 10.3389/fimmu.2020.02138

Figure 1.

Figure 1

GC-MS-based fecal metabolome profiles distinguish SLE patients from HCs. (A) Score plots based on OPLS-DA illustrated that the metabolic profiles of SLE patients and HCs were clearly separated. (B) Statistical validation of the OPLS-DA model by permutation test. (C) The VIP values of those metabolites have important contributions to distinguishing between SLE patients and HCs. (D) 2-Aminoalonic acid and glycolic acid were selected as potential biomarkers based on the S-plot. SLE, systemic lupus erythematosus; HCs, healthy controls; OPLS-DA, orthogonal partial least squares discriminant analysis; VIP, variable importance in the projection.